Molnupiravir (EIDD-2801/MK-4482) Supply Agreement for Pandemic Purposes

Concepts

• supply agreement
• pharmaceutical products
• sars
• first oral
• units of molnupiravir
• procurement of molnupiravir
• molnupiravir
• pandemic purposes
• eidd-2801
• antiviral drugs

Location

United Kingdom: London

Description

Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. So far there are no primary care antiviral drugs that can be easily dispensed specifically to treat SARS-CoV-2 and prevent its transmission in the community. This agreement is for the procurement of 480,000 units of Molnupiravir (EIDD-2801/MK-4482). It is one of the first oral and direct-acting antiviral drugs globally and the first to receive regulatory approval and is part of the UK’s multi-layered approach to COVID-19.

Total Quantity or Scope

Procurement of Molnupiravir (EIDD-2801/MK-4482).

Award Detail

Award Criteria

CPV Codes

• 33600000 - Pharmaceutical products

Legal Justification

Please see Annex D1 attached for more information.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors and (iii) impact fair competition between vendors.